LM22B-10
Based on 22 publication(s) in Google Scholar
LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor, and can induce TrkB, TrkC, AKT and ERK activation in vitro and in vivo.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.92%
- CAS 番号: 342777-54-2
- 分子式: C27H33ClN2O4
- 分子量:485.01
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
MedChemExpress(MCE)の使用を引用している文献 LM22B-10
More- Cell Mol Immunol. 2021 Jun;18(6):1489-1502. [Abstract]
- Adv Sci (Weinh). 2026 Jan 25:e11482. [Abstract]
- Cell Death Dis. 2026 Apr 10;17(1):498. [Abstract]
- Life Sci. 2021 Jan 1;264:118696. [Abstract]
- Front Pharmacol. 2022 Feb 21:13:826716. [Abstract]
- Mol Med Rep. 2020 Jul;22(1):67-76. [Abstract]
- Neurochem Res. 2020 Feb;45(2):345-353. [Abstract]
- Autoimmunity. 2023 Dec;56(1):2200908. [Abstract]
- FASEB J. 2021 May;35(5):e21526. [Abstract]
- J Immunol. 2021 Jun 1;206(11):2623-2637. [Abstract]
- J Immunol Res. 2020 Feb 10;2020:6457879. [Abstract]
- PLoS One. 2026 Mar 31;21(3):e0346011. [Abstract]
- Heart Lung Circ. 2025 Jul;34(7):704-718. [Abstract]
- Cytotechnology. 2025 Jun;77(3):116. [Abstract]
- Exp Ther Med. 2023 Apr 18;25(6):260. [Abstract]
- Actas Esp Psiquiatr. 2024 Oct;52(5):724-732. [Abstract]
- J Interferon Cytokine Res. 2021 Oct;41(10):375-384. [Abstract]
- Asian Pac J Trop Med. 2017 Dec;10(12):1172-1176. [Abstract]
- Blood Coagul Fibrinolysis. 2024 Jul 1;35(5):248-255. [Abstract]
- Research Square Preprint. 2023 Apr 28.
- Ann Transl Med. 2022 Nov;10(22):1238. [Abstract]
- Bioengineered. 2022 Jan;13(1):508-520. [Abstract]
生物活性
|
TrkB |
TrkC |
ERK |
Akt |
LM22B-10 exhibits maximum neurotrophic survival activity levels that are higher than those maximally achieved with BDNF (53 ± 7.2% above BDNF at 0.7 nM) and NT-3 (91 ± 8.6% above NT-3 at 0.7 nM) with an EC50 value of 200-300 nM. LM22B-10 (1000 nM) induces neurites of significantly larger average lengths, up to -40 μM. LM22B-10 (250-2000 nM) binds to TrkB-Fc and TrkC-Fc in a dose-dependent manner. LM22B-10 inhibits binding of BDNF to TrkB-expressing cells and NT-3 to TrkC-expressing cells. LM22B-10 promotes cell survival and functions preferentially through TrkB and TrkC. LM22B-10, but not BDNF or NT-3, promotes neurite outgrowth in an inhibitory environment. LM22B-10 induces patterns of Trk and downstream signaling activation that are distinct from those of BDNF and NT-3. LM22B-10 also induces TrkB, TrkC, AKT and ERK activation in hippocampal neurons in culture[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 342777-54-2
-
性状 Powder
-
分子量 485.01
-
分子式 C27H33ClN2O4
-
Color Light green to green
-
SMILES
ClC1=CC=C(C(C2=CC=C(N(CCO)CCO)C=C2)C3=CC=C(N(CCO)CCO)C=C3)C=C1
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (22)
-
Journal Impact Factor
-
Most Recent
-
Cell Mol Immunol
Spaceflight and simulated microgravity suppresses macrophage development via altered RAS/ERK/NFκB and metabolic pathways. [Abstract]2021 Jun;18(6):1489-1502. PMID: 31900461 -
Adv Sci (Weinh)
Inhibition of SLC11A1-Mediated Lysosomal Iron Accumulation in Microglia Promotes Repair Following White Matter Stroke. [Abstract]2026 Jan 25:e11482. PMID: 41580979 -
Cell Death Dis
DUSP5 suppresses esophageal squamous cell carcinoma by counteracting macrophage-derived AREG-ERK1/2 signaling and disrupting an oncogenic ERK1/2-ELK1-DUSP5 feedback circuitry. [Abstract]2026 Apr 10;17(1):498. PMID: 41956999 -
Life Sci
Curcumol inhibits KLF5-dependent angiogenesis by blocking the ROS/ERK signaling in liver sinusoidal endothelial cells. [Abstract]2021 Jan 1;264:118696. PMID: 33157090 -
Front Pharmacol
Sporoderm-Broken Spores of Ganoderma lucidum Sensitizes Ovarian Cancer to Cisplatin by ROS/ERK Signaling and Attenuates Chemotherapy-Related Toxicity. [Abstract]2022 Feb 21:13:826716. PMID: 35264959 -
Mol Med Rep
miR‑133b affects cell proliferation, invasion and chemosensitivity in renal cell carcinoma by inhibiting the ERK signaling pathway. [Abstract]2020 Jul;22(1):67-76. PMID: 32377748 -
Neurochem Res
Dexmedetomidine Inhibits Neuroinflammation by Altering Microglial M1/M2 Polarization Through MAPK/ERK Pathway. [Abstract]2020 Feb;45(2):345-353. PMID: 31823113 -
Autoimmunity
Sema3A inactivates the ERK/JNK signalling pathways to alleviate inflammation and oxidative stress in lipopolysaccharide-stimulated rat endothelial cells and lung tissues. [Abstract]2023 Dec;56(1):2200908. PMID: 37128697 -
FASEB J
2021 May;35(5):e21526. PMID: 33813773 -
J Immunol
β-Arrestin 2 Regulates Inflammatory Responses against Mycobacterium tuberculosis Infection through ERK1/2 Signaling. [Abstract]2021 Jun 1;206(11):2623-2637. PMID: 34001657 -
J Immunol Res
Chloroquine and Rapamycin Augment Interleukin-37 Expression via the LC3, ERK, and AP-1 Axis in the Presence of Lipopolysaccharides. [Abstract]2020 Feb 10;2020:6457879. PMID: 32104716 -
PLoS One
CAPG serves as a prognostic biomarker and promotes proliferation and migration in pancreatic ductal adenocarcinoma. [Abstract]2026 Mar 31;21(3):e0346011. PMID: 41915646 -
Heart Lung Circ
The Piezo1/Extracellular Signal-Regulated Kinase Signal Pathway Regulates Proliferation and Migration of Aortic Vascular Smooth Muscle Cells and Participates in Thoracic Aortic Aneurysm. [Abstract]2025 Jul;34(7):704-718. PMID: 40500623 -
Cytotechnology
IGFBP7 inhibition relieves LPS induced nucleus pulposus cell injury by regulating the ERK1/2 pathway. [Abstract]2025 Jun;77(3):116. PMID: 40488211 -
Exp Ther Med
ADAM metallopeptidase domain 10 knockdown enables podocytes to resist high glucose stimulation by inhibiting pyroptosis via MAPK pathway. [Abstract]2023 Apr 18;25(6):260. PMID: 37153901 -
Actas Esp Psiquiatr
Schisandrin A Alleviates Inflammation and Oxidative Stress in Aβ25-35-Induced Alzheimer's Disease in Vitro Model. [Abstract]2024 Oct;52(5):724-732. PMID: 39403912 -
J Interferon Cytokine Res
Interleukin-38 Suppresses Cell Migration and Proliferation and Promotes Apoptosis of Colorectal Cancer Cell Through Negatively Regulating Extracellular Signal-Regulated Kinases Signaling. [Abstract]2021 Oct;41(10):375-384. PMID: 34612721 -
Asian Pac J Trop Med
Regulating effect of glycyrrhetinic acid on bronchial asthma smooth muscle proliferation and apoptosis as well as inflammatory factor expression through ERK1/2 signaling pathway. [Abstract]2017 Dec;10(12):1172-1176. PMID: 29268974 -
Blood Coagul Fibrinolysis
Uvaol alleviates oxidative stress induced human umbilical vein endothelial cell injury by suppressing mitogen-activated protein kinase signaling pathway. [Abstract]2024 Jul 1;35(5):248-255. PMID: 38700418 -
-
Ann Transl Med
Targeted activation of ERK1/2 reduces ischemia and reperfusion injury in hyperglycemic myocardium by improving mitochondrial function. [Abstract]2022 Nov;10(22):1238. PMID: 36544682 -
Bioengineered
Lipocalin-2 silencing suppresses inflammation and oxidative stress of acute respiratory distress syndrome by ferroptosis via inhibition of MAPK/ERK pathway in neonatal mice. [Abstract]2022 Jan;13(1):508-520. PMID: 34969358
溶剤 & 溶解度
DMSO : 116.67 mg/mL (240.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.15 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.29 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 10 mg/mL (20.62 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
プロトコル
Mouse NIH-3T3 cells, mouse NIH-3T3 cells expressing TrkA (NIH-3T3-TrkA) or p75NTR (NIH-3T3-p75NTR), and NIH-3T3 cells expressing TrkB (NIH-3T3-TrkB) or TrkC (NIH-3T3-TrkC) are propagated in DMEM supplemented with 10% FBS and 200-400 μg/mL Geneticin (for Trk-expressing cells) or 400 μg/mL hygromycin (for p75NTR-expressing cells). Cells are seeded into 24-well plates (30,000 cells/well) and cultured in medium consisting of 50% PBS and 50% DMEM without supplements. Following exposure to growth factors (0.7 nM) or 1000 nM LM22B-10 for 72-96 h, cells are suspended in 50 μL lysis buffer, transferred to opaque 96-well culture plates and survival is measured using the ViaLight Assay.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
純度とドキュメンテーション
-
データシート (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0618 mL | 10.3091 mL | 20.6181 mL | 51.5453 mL |
| 5 mM | 0.4124 mL | 2.0618 mL | 4.1236 mL | 10.3091 mL | |
| 10 mM | 0.2062 mL | 1.0309 mL | 2.0618 mL | 5.1545 mL | |
| 15 mM | 0.1375 mL | 0.6873 mL | 1.3745 mL | 3.4364 mL | |
| 20 mM | 0.1031 mL | 0.5155 mL | 1.0309 mL | 2.5773 mL | |
| 25 mM | 0.0825 mL | 0.4124 mL | 0.8247 mL | 2.0618 mL | |
| 30 mM | 0.0687 mL | 0.3436 mL | 0.6873 mL | 1.7182 mL | |
| 40 mM | 0.0515 mL | 0.2577 mL | 0.5155 mL | 1.2886 mL | |
| 50 mM | 0.0412 mL | 0.2062 mL | 0.4124 mL | 1.0309 mL | |
| 60 mM | 0.0344 mL | 0.1718 mL | 0.3436 mL | 0.8591 mL | |
| 80 mM | 0.0258 mL | 0.1289 mL | 0.2577 mL | 0.6443 mL | |
| 100 mM | 0.0206 mL | 0.1031 mL | 0.2062 mL | 0.5155 mL |